Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
RESEARCH TOOLSreports
Holding DE:38I?
Track your performance easily
Blogger Sentiment
Sector Average
Bullish
Blogger Article Distribution
61% InvestorPlace
22% MotleyFool
5% SeekingAlpha
12% Others
The distribution of articles among the main online Financial Blogging platforms.
Top Blogger Bearish Predictions
Not enough top blogger opinions at this time
Please return soon. This page is being updated.
Recent negative articles by top bloggers.
Top Blogger Bullish Predictions
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case
3 High-Risk Undervalued Stocks for Aggressive Investors Targeting 35%+ Upside
Recent positive articles by top bloggers.
Financial Blogger Predictions
Blogger Performance
Any
Blogger Sentiment
Any
The Motley Fool
Bullish
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
The Motley Fool
Bullish
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
TipRanks Contributor
Bullish
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
FAQ
What do Seeking Alpha bloggers think of DE:38I?
Seeking Alpha’s Ian Cooper has a Bullish Sentiment.
What do Motley Fool contributors think of DE:38I?
Currently there's no blogger sentiment for DE:38I.
What Is DE:38I’s Blogger Sentiment?
DE:38I’s Blogger Sentiment is Bullish.
What was the most recent blogger prediction for DE:38I?
The most recent blogger prediction for DE:38I was made by George Budwell , who was Bullish on the stock.
How can I follow the stock ratings of top Top Financial Bloggers?
Head over to our Expert Center to see a list of the Top 100 Financial Bloggers and follow the financial bloggers of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.